Crescent Biopharma, Inc. CBIO
Crescent Biopharma, Inc. (Nasdaq: CBIO) is an oncology drug developer. Its lead program, CR-001 (SKB118), is in Phase 1 for Solid tumors incl. NSCLC (PD-1 x VEGF bispecific antibody). Its next catalyst on record is CR-002: Global Phase 1/2 APOLLO trial of CR-002 expected to initiate in fourth quarter of 2026. (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: CR-002 — Global Phase 1/2 APOLLO trial of CR-002 expected to initiate in fourth quarter of 2026. (Q4 2026). 18 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| CR-001 + sac-TMT (Kelun-sponsored China Ph2) | NSCLC | antibody | Phase 2 |
| CR-001 (PD-1 x VEGF bispecific; ASCEND global Ph1/2) | Up to eight solid tumor types incl. NSCLC | antibody | Phase 1 |
| CR-003 (SKB105, ITGB6 ADC; China Ph1/2 run by Kelun) | Solid tumors | biologic-other | Phase 1 |
| CR-002 (PD-L1 ADC) | Solid tumors | biologic-other | Pre-clinical |
Recent results and decisions
- Oct 15, 2026started Enrollment has commenced in the standard of care chemotherapy combination expansion cohorts of the ASCEND trial for CR-001.
Enrollment has also commenced in the standard of care chemotherapy combination expansion cohorts of ASCEND.
Filing - Oct 15, 2026n/a Kelun-Biotech granted Crescent exclusive rights to CR-003 (SKB105) outside of Greater China.
Kelun-Biotech granted the Company exclusive rights to research, develop, and commercialize CR-003 (SKB105), an integrin-beta 6-targeted ADC, in the United States, Europe and all markets outside of Greater China.
Filing - Oct 15, 2026started Crescent commenced enrollment in standard of care chemotherapy combination expansion cohorts of CR-001 ASCEND trial across multiple tumor types.
Enrollment has also commenced in the standard of care chemotherapy combination expansion cohorts of ASCEND.
Filing
2 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 oncology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.